Last updated on July 2018

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-04/ECHO-305-04)

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).

Clinical Study Identifier: NCT03322540

Contact Investigators or Research Sites near you

Start Over

Incyte Corporation Call Center (US)

Robert Bosch Krankenhaus Klinik Schillerhoehe
Gerlingen, Germany
  Connect »